Biotech


  • Antibodies autoimmune disease
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Immunovant changes up plans for closely watched autoimmune drugs

    The company is prioritizing development of an earlier so-called FcRn inhibitor, a type of medicine that’s shown promise treating multiple inflammatory conditions. 

    By Kristin Jensen • May 30, 2024
  • A stock market graph overlaid on a laptop and stack of coins.
    Image attribution tooltip
    Stadtratte via Getty Images
    Image attribution tooltip
    Emerging biotech

    CinCor’s ‘hub-and-spoke’ parent nabs new funding to build its next biotechs

    The $73 million round for CinRx Pharma, which created a startup AstraZeneca bought last year, will help fund subsidiaries making drugs for obesity, irritable bowel syndrome and gastroparesis. 

    By May 30, 2024
  • Explore the Trendline
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • Spermatozoon is injected into an ovum with help of microneedle and holding pipette underneath a microscope
    Image attribution tooltip
    Svitlana Hulko via Getty Images
    Image attribution tooltip
    Emerging biotech

    A biotech working on a new approach to IVF raises $33M in fresh funding

    The Series B funding from Two Sigma Ventures, RA Capital and others will help Gameto develop technology it says could replace hormonal injections and shorten the IVF process.

    By May 29, 2024
  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Zorica Nastasic via Getty Images
    Image attribution tooltip

    Merck to buy eye drug developer for $1.3B

    An acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.

    By Kristin Jensen • May 29, 2024
  • Robot arm DNA
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Can robots break the cell therapy bottleneck?

    A partnership between cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could address manufacturing hurdles, the CEOs said.

    By Michael Gibney • May 29, 2024
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Insmed shares double as lung drug data convince Wall Street

    After reporting positive clinical trial results for its drug brensocatib, Insmed plans to later this year file for U.S. approval in bronchiectasis that’s not associated with cystic fibrosis.

    By May 28, 2024
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Agios cashes in on cancer drug again with $905M Royalty Pharma deal

    The deal involves royalties for a brain cancer drug Agios previously sold off and that Royalty Pharma thinks could generate more than $1 billion in U.S. sales.

    By May 28, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Roche’s Sabry retires; Duchenne drug fails confirmatory test

    The veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative Phase 3 data and Merck unveiled new breast cancer results for Keytruda.

    By BioPharma Dive staff • May 28, 2024
  • A  3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Orna, a circular RNA specialist, acquires a buzzy startup

    After laying off staff late last year, Orna is expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.

    By May 23, 2024
  • The Nasdaq Marketplace is seen on March 01, 2024 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Cytokinetics secures up to $575M in royalty deal, frustrating investors

    The biotech’s decision to give Royalty Pharma a greater share of future drug sales suggests a lower likelihood it is readying to be acquired, analysts said.

    By May 23, 2024
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B

    The deal, only Biogen’s third since the start of 2018, is a sign the company is open to branching out beyond the neurological drugs that have long been its focus. 

    By Kristin Jensen • May 22, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Regeneron faces new biosimilar threats; an AI biotech lays off staff

    Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers. 

    By BioPharma Dive staff • May 22, 2024
  • A portrait of Philip Larsen, CEO of SixPeaks Bio AG.
    Image attribution tooltip
    Permission granted by SixPeaks Bio AG
    Image attribution tooltip
    Obesity drugs

    SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca

    AstraZeneca has an exclusive chance to buy the startup, which is developing a muscle-protecting weight loss medicine, within the next two years.

    By May 22, 2024
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly partners with Aktis, deepening radiopharma investment

    The collaboration, which gives Lilly access to Aktis’ technology in return for $60 million, adds to a flurry of dealmaking in the radiopharma field.

    By May 21, 2024
  • A person works in a laboratory at AltruBio.
    Image attribution tooltip
    Permission granted by AltruBio
    Image attribution tooltip
    Emerging biotech

    AltruBio lands up to $225M after shift to immune drug research

    Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.

    By May 21, 2024
  • A headshot of Cyrus Mozayeni, CEO of Pheon Therapeutics.
    Image attribution tooltip
    Permission granted by Pheon Therapeutics
    Image attribution tooltip
    Emerging biotech

    Pheon rides wave of ADC interest with $120M financing

    CEO Cyrus Mozayeni said the company is taking a different approach than other developers of antibody-drug conjugates, though it’s keeping details close.

    By May 21, 2024
  • An illustration of a neuron cell network on a black background.
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Forbion-backed biotech Progentos debuts with $65M for MS drug

    Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for multiple sclerosis through "proof of concept” testing.

    By May 20, 2024
  • A stock photo of blocks arranged to illustrate layoffs
    Image attribution tooltip
    Andrii Yalanskyi via Getty Images
    Image attribution tooltip

    BIO to restructure, lay off staff in shakeup of lobbying group

    Thirty employees will leave as part of the reorganization, which the group said is meant to bring "stronger focus and greater impact" to its work.

    By May 20, 2024
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Dyne shares jump on trial data for muscle disease drugs

    Updated study results for the biotech’s medicines for myotonic dystrophy Type 1 and Duchenne muscular dystrophy appeared to impress analysts and investors on Wall Street.

    By May 20, 2024
  • Image attribution tooltip
    Carl Court via Getty Images
    Image attribution tooltip

    European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug

    Rather than endorse the recommendation of the EMA, the commission called for a new review for Translarna that considers “the totality of the evidence” compiled to date.

    By May 20, 2024
  • Abstract
    Image attribution tooltip

    vitanovski/stock.adobe.com

    Image attribution tooltip
    Sponsored by IO Biotech

    Therapies designed to dismantle cancer’s escape mechanisms show promise for patients

    Hear from IO Biotech CEO Dr. Mai-Britt Zocca about the potential of therapeutic vaccines to strip the defenses used by cancer cells to keep the immune system at bay.

    By Mai-Britt Zocca, Ph.D., founder and chief executive officer, IO Biotech • May 20, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Erasca restructures; Novartis moves to complete MorphoSys deal

    The cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere, Novartis secured sufficient support for its $3 billion buyout and Bristol Myers won a new CAR-T approval.

    By BioPharma Dive staff • May 17, 2024
  • Weight loss GLP-1
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Obesity drugs

    Investors put $400M into biotech licensing obesity drugs from China

    The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

    By May 16, 2024
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip
    ALS drug development

    Biogen, Ionis shelve ALS drug following study failure

    While results indicated the drug works as intended, it didn’t have enough of an effect on a protein that’s become integral to many ALS research programs.

    By May 16, 2024
  • A blurred photo of an empty laboratory
    Image attribution tooltip
    Ozankutsal via Getty Images
    Image attribution tooltip

    Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate

    The company will cut its workforce by half and shuffle leadership as it discontinues testing of the drug trastuzumab imbotolimod.

    By May 15, 2024